UroGen Pharma Ltd. (URGN) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Elizabeth A. Barrett	President, Chief Executive Officer & Director	2.19M	1962
Christopher Degnan	Chief Financial Officer	561,797	1980
Mark Schoenberg	Chief Medical Officer	730,240	1958
Jason Drew Smith	General Counsel, Chief Compliance Officer & Corporate Secretary	978,418	1972
David Lin	Chief Commercial Officer	0	N/A
Michael J. Louie	Chief Development Officer	0	N/A
Timothy Simon	Senior Vice President of Business Development & Portfolio Strategy	0	N/A
James Ottinger	Executive Vice President of Regulatory Affairs & Quality	0	N/A
Alison Hardgrove	Senior Vice President of Human Resources	0	N/A
Marina Konorty	Executive Vice President of Research & Development and Technical Operations	0	N/A
Vincent I. Perrone	Senior Director of Investor Relations	0	N/A

Name

Title

Pay

Year Born

Elizabeth A. Barrett

President, Chief Executive Officer & Director

2.19M

1962

Christopher Degnan

Chief Financial Officer

561,797

1980

Mark Schoenberg

Chief Medical Officer

730,240

1958

Jason Drew Smith

General Counsel, Chief Compliance Officer & Corporate Secretary

978,418

1972

David Lin

Chief Commercial Officer

N/A

Michael J. Louie

Chief Development Officer

N/A

Timothy Simon

Senior Vice President of Business Development & Portfolio Strategy

N/A

James Ottinger

Executive Vice President of Regulatory Affairs & Quality

N/A

Alison Hardgrove

Senior Vice President of Human Resources

N/A

Marina Konorty

Executive Vice President of Research & Development and Technical Operations

N/A

Vincent I. Perrone

Senior Director of Investor Relations

N/A

Description

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.